Vanguard Group’s Cogentix Medical, Inc. CGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-1,031,874
| Closed | -$3.97M | – | 4181 |
|
|
2018
Q1 | $3.97M | Buy |
1,031,874
+429,920
| +71% | +$1.35M | ﹤0.01% | 3238 |
|
|
2017
Q4 | $1.9M | Buy |
601,954
+159,658
| +36% | +$460K | ﹤0.01% | 3440 |
|
|
2017
Q3 | $1.13M | Buy |
442,296
+222,913
| +102% | +$488K | ﹤0.01% | 3555 |
|
|
2017
Q2 | $381K | Sell |
219,383
-290,028
| -57% | -$497K | ﹤0.01% | 3777 |
|
|
2017
Q1 | $917K | Buy |
509,411
+7,300
| +1% | +$14.4K | ﹤0.01% | 3601 |
|
|
2016
Q4 | $1.01M | Sell |
502,111
-18,436
| -4% | -$37.7K | ﹤0.01% | 3558 |
|
|
2016
Q3 | $947K | Buy |
520,547
+10,820
| +2% | +$14K | ﹤0.01% | 3588 |
|
|
2016
Q2 | $490K | Hold |
509,727
| – | – | ﹤0.01% | 3799 |
|
|
2016
Q1 | $561K | Sell |
509,727
-1,762
| -0.3% | -$1.98K | ﹤0.01% | 3764 |
|
|
2015
Q4 | $660K | Sell |
511,489
-28
| -0% | -$38 | ﹤0.01% | 3751 |
|
|
2015
Q3 | $634K | Sell |
511,517
-940
| -0.2% | -$1.44K | ﹤0.01% | 3780 |
|
|
2015
Q2 | $830K | Buy |
+512,457
| New | +$839K | ﹤0.01% | 3715 |
|
Vanguard Group's CGNT Position: Q2 2018 in Review
Vanguard Group sold out of Cogentix Medical, Inc. (CGNT) in Q2 2018, closing a stake of 1,031,874 shares — an estimated $3.97M sold.
Vanguard Group first reported a position in CGNT in Q2 2015 and held it in 12 quarters. The position peaked at $3.97M in Q1 2018. 0 funds tracked by Wall St. Rank hold CGNT as of Q2 2018.
- Vanguard Group reported no remaining Cogentix Medical, Inc. position as of Q2 2018 after selling out during the quarter.
- Vanguard Group sold 1,031,874 Cogentix Medical, Inc. shares in Q2 2018, an estimated $3.97M.
- Vanguard Group first reported a position in Cogentix Medical, Inc. in Q2 2015 and held it in 12 quarters.
- Vanguard Group's Cogentix Medical, Inc. position peaked at $3.97M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Cogentix Medical, Inc. as of Q2 2018.
Based on Vanguard Group's 13F filing for Q2 2018, filed 14 Aug 2018.